NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Al:If DC VAX L is needed( see Linda Liau, MD, PhD, MBA, and Yagmur Muftuoglu, PhD editorial in JAMA 5/21/20) in combo with Opdivio and Keytruda in GBM in order for them to achieve an improvement over SOC(BMS phase 3 clinical trial ,Checkmate 143, proved that Opdivio did not improve MOS in GBM patients compared to MOS achieved with bevacizumab (Avastin)), what do you think a large Pharma company would pay to own DC Vax L ?




See Model Portfolio #7 at www.alphavestcapital.com for source material.